336 related articles for article (PubMed ID: 28511325)
1. [Feasibility of the 2014 European guidelines risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy in Chinese patients].
Zhu SH; Li Y; Huang W; Jiang H; Li SN; Chen L; Huang S; Yu HS; Xu B
Zhonghua Xin Xue Guan Bing Za Zhi; 2017 May; 45(5):404-408. PubMed ID: 28511325
[No Abstract] [Full Text] [Related]
2. Validation of the 2014 European Society of Cardiology guidelines risk prediction model for the primary prevention of sudden cardiac death in hypertrophic cardiomyopathy.
Vriesendorp PA; Schinkel AF; Liebregts M; Theuns DA; van Cleemput J; Ten Cate FJ; Willems R; Michels M
Circ Arrhythm Electrophysiol; 2015 Aug; 8(4):829-35. PubMed ID: 25922410
[TBL] [Abstract][Full Text] [Related]
3. Improvement in sudden cardiac death risk prediction by the enhanced American College of Cardiology/American Heart Association strategy in Chinese patients with hypertrophic cardiomyopathy.
Liu J; Wu G; Zhang C; Ruan J; Wang D; Zhang M; Wang L; Yang Y; Li X; Wang Y; Hui R; Zou Y; Kang L; Wang J; Song L
Heart Rhythm; 2020 Oct; 17(10):1658-1663. PubMed ID: 32311532
[TBL] [Abstract][Full Text] [Related]
4. A validation study of the 2003 American College of Cardiology/European Society of Cardiology and 2011 American College of Cardiology Foundation/American Heart Association risk stratification and treatment algorithms for sudden cardiac death in patients with hypertrophic cardiomyopathy.
O'Mahony C; Tome-Esteban M; Lambiase PD; Pantazis A; Dickie S; McKenna WJ; Elliott PM
Heart; 2013 Apr; 99(8):534-41. PubMed ID: 23339826
[TBL] [Abstract][Full Text] [Related]
5. [Predicting value of 2014 European guidelines risk prediction model for sudden cardiac death (HCM Risk-SCD) in Chinese patients with hypertrophic cardiomyopathy].
Li WX; Liu LW; Wang J; Zuo L; Yang F; Kang N; Lei CH
Zhonghua Xin Xue Guan Bing Za Zhi; 2017 Dec; 45(12):1033-1038. PubMed ID: 29325362
[No Abstract] [Full Text] [Related]
6. Predicting therapies in Japanese hypertrophic cardiomyopathy patients with an implantable cardioverter-defibrillator using the 2014 European Society of Cardiology guidelines.
Nakano M; Kondo Y; Nakano M; Kajiyama T; Miyazawa K; Hayashi T; Ito R; Takahira H; Kobayashi Y
Heart Vessels; 2021 Jan; 36(1):99-104. PubMed ID: 32666207
[TBL] [Abstract][Full Text] [Related]
7. Validation of the new American College of Cardiology/American Heart Association Guidelines for the risk stratification of sudden cardiac death in a large Mediterranean cohort with Hypertrophic Cardiomyopathy.
Zegkos T; Tziomalos G; Parcharidou D; Ntelios D; Papanastasiou CA; Karagiannidis E; Gossios T; Rouskas P; Katranas S; Paraskevaidis S; Karvounis H; Efthimiadis G
Hellenic J Cardiol; 2022; 63():15-21. PubMed ID: 34147674
[TBL] [Abstract][Full Text] [Related]
8. Validation of the HCM Risk-SCD model in patients with hypertrophic cardiomyopathy following alcohol septal ablation.
Liebregts M; Faber L; Jensen MK; Vriesendorp PA; Hansen PR; Seggewiss H; Horstkotte D; Adlova R; Michels M; Bundgaard H; Ten Berg JM; Veselka J
Europace; 2018 Sep; 20(FI2):f198-f203. PubMed ID: 29016960
[TBL] [Abstract][Full Text] [Related]
9. The amount of late gadolinium enhancement outperforms current guideline-recommended criteria in the identification of patients with hypertrophic cardiomyopathy at risk of sudden cardiac death.
Freitas P; Ferreira AM; Arteaga-Fernández E; de Oliveira Antunes M; Mesquita J; Abecasis J; Marques H; Saraiva C; Matos DN; Rodrigues R; Cardim N; Mady C; Rochitte CE
J Cardiovasc Magn Reson; 2019 Aug; 21(1):50. PubMed ID: 31412875
[TBL] [Abstract][Full Text] [Related]
10. Enhanced American College of Cardiology/American Heart Association Strategy for Prevention of Sudden Cardiac Death in High-Risk Patients With Hypertrophic Cardiomyopathy.
Maron MS; Rowin EJ; Wessler BS; Mooney PJ; Fatima A; Patel P; Koethe BC; Romashko M; Link MS; Maron BJ
JAMA Cardiol; 2019 Jul; 4(7):644-657. PubMed ID: 31116360
[TBL] [Abstract][Full Text] [Related]
11. International External Validation Study of the 2014 European Society of Cardiology Guidelines on Sudden Cardiac Death Prevention in Hypertrophic Cardiomyopathy (EVIDENCE-HCM).
O'Mahony C; Jichi F; Ommen SR; Christiaans I; Arbustini E; Garcia-Pavia P; Cecchi F; Olivotto I; Kitaoka H; Gotsman I; Carr-White G; Mogensen J; Antoniades L; Mohiddin SA; Maurer MS; Tang HC; Geske JB; Siontis KC; Mahmoud KD; Vermeer A; Wilde A; Favalli V; Guttmann OP; Gallego-Delgado M; Dominguez F; Tanini I; Kubo T; Keren A; Bueser T; Waters S; Issa IF; Malcolmson J; Burns T; Sekhri N; Hoeger CW; Omar RZ; Elliott PM
Circulation; 2018 Mar; 137(10):1015-1023. PubMed ID: 29191938
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of the 2014 European Society of Cardiology guideline on sudden cardiac death in hypertrophic cardiomyopathy: a systematic review and meta-analysis.
O'Mahony C; Akhtar MM; Anastasiou Z; Guttmann OP; Vriesendorp PA; Michels M; Magrì D; Autore C; Fernández A; Ochoa JP; Leong KMW; Varnava AM; Monserrat L; Anastasakis A; Garcia-Pavia P; Rapezzi C; Biagini E; Gimeno JR; Limongelli G; Omar RZ; Elliott PM
Heart; 2019 Apr; 105(8):623-631. PubMed ID: 30366935
[TBL] [Abstract][Full Text] [Related]
13. Validation of the 2014 European Society of Cardiology Sudden Cardiac Death Risk Prediction Model in Hypertrophic Cardiomyopathy in a Reference Center in South America.
Fernández A; Quiroga A; Ochoa JP; Mysuta M; Casabé JH; Biagetti M; Guevara E; Favaloro LE; Fava AM; Galizio N
Am J Cardiol; 2016 Jul; 118(1):121-6. PubMed ID: 27189816
[TBL] [Abstract][Full Text] [Related]
14. Validation of the 2020 AHA/ACC Risk Stratification for Sudden Cardiac Death in Chinese Patients With Hypertrophic Cardiomyopathy.
Dong Y; Yang W; Chen C; Ji J; Zheng W; Zhang F; Yang B; Li X; Zhou X
Front Cardiovasc Med; 2021; 8():691653. PubMed ID: 34485400
[No Abstract] [Full Text] [Related]
15. Prediction of sudden death risk in obstructive hypertrophic cardiomyopathy: Potential for refinement of current criteria.
Desai MY; Smedira NG; Dhillon A; Masri A; Wazni O; Kanj M; Sato K; Thamilarasan M; Popovic ZB; Lever HM
J Thorac Cardiovasc Surg; 2018 Aug; 156(2):750-759.e3. PubMed ID: 29735354
[TBL] [Abstract][Full Text] [Related]
16. Prevention of Sudden Cardiac Death in Hypertrophic Cardiomyopathy: What has Changed in The Guidelines?
Reis L; Teixeira R; Fernandes A; Almeida I; Madeira M; Silva J; Botelho A; Pais J; Nascimento J; Gonçalves L
Arq Bras Cardiol; 2018 Jun; 110(6):524-531. PubMed ID: 30226910
[TBL] [Abstract][Full Text] [Related]
17. Validation of the Risk Stratification for Sudden Cardiac Death in Chinese Patients With Hypertrophic Cardiomyopathy.
Qi W; Pu L; Zhang J; Chen H; Tang Z; Wang J; Han Y; Chen Y
Curr Probl Cardiol; 2023 Nov; 48(11):101875. PubMed ID: 37331610
[TBL] [Abstract][Full Text] [Related]
18. Assessment of late gadolinium enhancement in hypertrophic cardiomyopathy improves risk stratification based on current guidelines.
Wang J; Yang S; Ma X; Zhao K; Yang K; Yu S; Yin G; Dong Z; Song Y; Cui C; Li J; Wang C; Hao J; Lu M; Chen X; Zhao S
Eur Heart J; 2023 Dec; 44(45):4781-4792. PubMed ID: 37795986
[TBL] [Abstract][Full Text] [Related]
19. ESC sudden-death risk model in hypertrophic cardiomyopathy: Incremental value of quantitative contrast-enhanced CMR in intermediate-risk patients.
Hinojar R; Zamorano JL; Gonzalez Gómez A; Plaza Martin M; Esteban A; Rincón LM; Portugal JC; Jimenez Nácher JJ; Fernández-Golfín C
Clin Cardiol; 2017 Oct; 40(10):853-860. PubMed ID: 28614597
[TBL] [Abstract][Full Text] [Related]
20. A validation study of the European Society of Cardiology guidelines for risk stratification of sudden cardiac death in childhood hypertrophic cardiomyopathy.
Norrish G; Ding T; Field E; McLeod K; Ilina M; Stuart G; Bhole V; Uzun O; Brown E; Daubeney PEF; Lota A; Linter K; Mathur S; Bharucha T; Kok KL; Adwani S; Jones CB; Reinhardt Z; Omar RZ; Kaski JP
Europace; 2019 Oct; 21(10):1559-1565. PubMed ID: 31155643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
